NIO
NICOTINIC ACID
Created: | 1999-07-08 |
Last modified: | 2024-10-02 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 14 |
Chiral Atom Count | 0 |
Bond Count | 14 |
Aromatic Bond Count | 6 |
Chemical Component Summary | |
---|---|
Name | NICOTINIC ACID |
Systematic Name (OpenEye OEToolkits) | pyridine-3-carboxylic acid |
Formula | C6 H5 N O2 |
Molecular Weight | 123.109 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C(O)c1cccnc1 |
SMILES | CACTVS | 3.341 | OC(=O)c1cccnc1 |
SMILES | OpenEye OEToolkits | 1.5.0 | c1cc(cnc1)C(=O)O |
Canonical SMILES | CACTVS | 3.341 | OC(=O)c1cccnc1 |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | c1cc(cnc1)C(=O)O |
InChI | InChI | 1.03 | InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9) |
InChIKey | InChI | 1.03 | PVNIIMVLHYAWGP-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB00627 |
---|---|
Name | Niacin |
Groups |
|
Description | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] |
Synonyms |
|
Brand Names |
|
Indication | Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565] |
Categories |
|
ATC-Code |
|
CAS number | 59-67-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Hydroxycarboxylic acid receptor 3 | MNRHHLQDHFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALW... | unknown | agonist |
Diacylglycerol O-acyltransferase 2 | MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSAL... | unknown | inhibitor |
Hydroxycarboxylic acid receptor 2 | MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALW... | unknown | agonist |
Nicotinate-nucleotide pyrophosphorylase [carboxylating] | MDAEGLALLLPPVTLAALVDSWLREDCPGLNYAALVSGAGPSQAALWAKS... | unknown | binder |
Nicotinamide N-methyltransferase | MESGFTSKDTYLSHFNPRDYLEKYYKFGSRHSAESQILKHLLKNLFKIFC... | unknown | binder |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL573 |
PubChem | 117629482, 938 |
ChEMBL | CHEMBL573 |
ChEBI | CHEBI:15940 |
CCDC/CSD | AWUDEB, NICOAC01, GADQEL |
COD | 2311082, 2311084 |